Product: Cefmenoxime (hydrochloride)
LRRK2 Antibody Summary
| Immunogen |
Residues 2506-2522 NLEKHIEVRKELAEKMR of the human 260 kDa LRRK2 protein.
|
| Specificity |
LRRK2
|
| Clonality |
Polyclonal
|
| Host |
Rabbit
|
| Gene |
LRRK2
|
| Purity |
Immunogen affinity purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
| Application Notes |
This antibody may be used for western blot.
The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
| Theoretical MW |
260 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors. |
Reactivity Notes
Reacts with Human. 88% sequence identity with mouse and rat proteins
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
|
| Buffer |
PBS
|
| Preservative |
0.02% Sodium Azide
|
| Concentration |
1 mg/ml
|
| Purity |
Immunogen affinity purified
|
Alternate Names for LRRK2 Antibody
- augmented in rheumatoid arthritis 17
- AURA17
- Dardarin
- DKFZp434H2111
- EC 2.7.11.1
- FLJ45829
- leucine-rich repeat kinase 2
- leucine-rich repeat serine/threonine-protein kinase 2
- LRRK2
- PARK8
- PARK8DARDARIN
- Parkinson disease (autosomal dominant) 8
- RIPK7
- ROCO2
Background
The novel LRRK2 gene (also known as PARK8), is responsible for up to 6% of all autosomal dominant Parkinsons disease (PD). LRRK2 missense mutations segregate with PARK8-linked PD and are implicated in other neurodegenerative diseases involving alpha-synuclein and tau pathology.